'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

'药品兄弟'马丁·香克利告诉投资者要开空SAVA，股票在第三阶段更新后下跌超过80%。

Benzinga · 2024/11/25 10:07

Cassava Sciences (NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.

cassava sciences（纳斯达克:SAVA）股票周一下跌，该公司分享了针对阿尔茨海默病治疗的第三阶段试验的最新消息，这一消息受到市场广泛关注。

Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock's crash Sunday night.

马丁·舒克雷利，药品行业内的知名人物，预测了该股票在周日夜间的崩盘。

What Happened: Cassava Sciences reported that its Phase 3 topline results for the ReThink-ALZ study on Simufilam did not meet primary endpoints, sending shares significantly lower to start the trading week.

发生了什么：cassava sciences报告指出，其关于Simufilam的ReThink-ALZ研究的第三阶段初步结果未能达到主要终点，使得股票在交易周初大幅下跌。

The company said it intends to present the data at an upcoming meeting, and Simufilam showed a favorable safety...

该公司表示，计划在即将举行的会议上展示...

登录免费看全文

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

风险及免责提示

声明